Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from not yet recruiting to recruiting.
- 17 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.
- 06 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.